improvement in overall survival in a small subset of patients. Clearly, the incidence of MPE and lack of effective treatments has created an urgent unmet need to develop an effective treatment.

Our studies of the pleural secretome in non-small cell lung cancer and mesothelioma, as well as extensive secretomic data in MPE from other cancers, indicate that the IL-6/IL-6Rα axis is prominent in pleural effusions and drives the epithelial to mesenchymal transition (EMT). We have identified additional cytokines that are absent in normal pleural fluid but prominent in malignant effusions. We have also found that MPE T cells, removed from their environment, are capable of expansion in culture, polyfunctional cytokine response, and are cytolytic to autologous tumor. Because the pleural space is lined with mesothelial cells joined by tight junctions, we hypothesize that it acts as a cytokine-rich bioreactor which promotes EMT in cancer cells metastatic to the pleura, and redirects the abundant immune infiltrate to promote, rather than inhibit, tumor growth. We hypothesize that as a master cytokine, IL-6 and its soluble receptor drive this process. Therefore, local blockade of sIL-6Rα will alter the pleural cytokine milieu, inhibiting aggressive tumor behavior and promoting anti-tumor immune response. Once unleashed in the pleural space, tumor-specific T cells could be expected to migrate to the periphery through the draining lymphatics and respond to extra-pleural metastases. Further, based on our current data, we are confident that the 100 million MPE T cells that are routinely recovered during routine therapeutic MPE drainage can be expanded in culture for an adoptive cellular therapy product that is faster, better and cheaper than conventional solid-tumor derived culture-expanded tumor infiltrating lymphocytes (TIL).

What remains to be determined is whether blockade of dominant cytokines in MPE together with anti-PD-1/PD-L1 therapy can condition the pleural environment sufficiently to support and expand the existing anti-tumor responses.

Combining the knowledge derived from these studies we propose to devise a personalized combined treatment strategy that conditions the pleural environment without incurring systemic toxicities and facilitates local and systemic anti-tumor immune response.

https://doi.org/10.1016/j.htct.2021.10.954

Sp10

CAR T-CELL

Francesco Saglio

Chimeric Antigen Receptor (CAR)-T cell therapy is emerging as one of the most powerful and promising therapeutictool for the treatment of malignat diseases. CAR-T cells are T-lymphocytes modified *in vitro* to harbor an artificial molecular construct (CAR) made by an extracellular domain consisting of a single-chain variable fragment (scFv) recognizing a specific tumor antigen joined to a transmembrane domain which is linked to the signaling unit CD3ζ and co-stimulatory units CD28 or 4-1BB of the T-cell receptor, making them capable to

recognize and to kill tumor's cell in a HLA-independent manner. CAR T-cell therapy consists in the selection of patient's normal T-cells via leukapheresis, activation, transduction to express CARs using lentiviral or retroviral vectors, expansion of transduced cells and infusion of the final product back to the patient. After the CAR T-cells are infused back into the patient, the engineered cells proliferate, recognize and kill tumor cells bearing the specific antigen the CAR is directed against.

In recent years US Food and Drug Administration (FDA) and European Medicine Agency (EMA) approved CD19 CAR T-cells in patients affected by relapsed and refractory ALL under the age of 25 years, adult patients affected by Non-Hodgkin Lymphomas and more recently adult patients affected by Multiple Myeloma and this technology is moving from an experimental approach available for very selected patients treated in a small number of Centers to a standard-of-care therapy available almost worldwide.

The diffusion of commercially available CAR-T cells has increased the number of patients treated by this cell therapy products and has also permitted to confirm their safety and efficacy profile in the "real life".

The diffusion of this technology requires a re-definition of the role of all the other therapy options currently available including other forms of immuno-therapy as monoclonal antibodies, bi-specific monoclonal antibodies and, upon all, allogeneic hematopoietic stem cell transplantation (alloHSCT).

Until now data are limited, and the above-mentioned question is far from being answered but there are some observations derived from pivotal clinical trials that probably will help us in building future trials aimed to define this topic.

Another open question is represented by the persistence of these cells in the patients that is related to the definition of the need for patients responding to CAR-T cells to proceed to other therapies, especially to alloHSCT, to consolidate disease remission. Moreover CAR-T cells are characterized by some peculiar side effects as the Cytokines Release Syndrome or CNS toxicity that if are not properly detected and treated may lead to very severe consequences with a significant mortality rate.

Finally, some technological, practical and economical considerations need to be defined in order to extend the use of this technology worldwide, in respect to the other currently available therapies.

https://doi.org/10.1016/j.htct.2021.10.955

Sp11

TARGETED THERAPY IN AML TREATMENT

Giovanni Martinelli

Prof. Martinelli will speak about new drugs in the treatment of acute leukemias, starting from mechanisms of actions of the compounds and explaining strategies for clinical research.

Venetoclax is a bcl-2 inhibitor that is entering in the therapy of AML. The use of venetoclax will be explored with particular attention to combination with purine and pyrimidine analogs and metabolism.

Ponatinib is a pan TKI with particular activity on BCR-ABL1 fusion protein, VEGF and FLT3, and a high number of collateral activity on immunogenic cell death and environment. Ponatinib is able to protect against the emergence of BCR-ABL1 mutations. Ponatinib was used in new-onset and relapse-refractory Ph+ ALL. The use of ponatinib may be further expanded in Ph-like/3C-UP ALL and in subcategories of AML.

Gilteritinib is an FLT3, AXL, and ALK inhibitor with single-agent activity in R/R AML. Gilteritinib multikinase inhibition and differentiation effects will be explored, together with combination with chemotherapy.

MDM2 and Menin inhibition are appealing strategies in the treatment of predefined subsets of AML, preliminary laboratory data will be presented.

https://doi.org/10.1016/j.htct.2021.10.956

Sp12

HAEMOPHILIA AND NURSING CARE

Marcela Ganzella

Hemophilia is a rare, inherited, X-chromosome-linked bleeding disorder resulting from a deficiency of clotting factor VIII (hemophilia A) or factor IX (hemophilia B). In the world, according to the World Federation of Hemophilia 2019, there are currently approximately 157,517 people diagnosed with Hemophilia A and 31,997 Hemophilia B. Nurses may be involved in providing direct clinical care, education, support and self-management for patients and their families. In this presentation we will talk about important aspects of hemophilia: pathophysiology, nursing care and concern, treatment pathway and patient education

https://doi.org/10.1016/j.htct.2021.10.957

Sp13

RHABDOMYOSARCOMA

Mehmet Fatih Okçu

Rhabdomyosarcoma is the most common soft tissue sarcoma in childhood. While based on the cooperative group work from US and Europe diagnosis and treatment guidelines exist management controversies exist for newly diagnosed intermediate and high risk disease and in patients with relapses. The presentation will discuss further details on management of these patient groups in the light of recent published work.

Non-rhabdomyosarcomatous soft tissue sarcomas (NRSTS)

NRSTS are large group of heterogenous group of soft tissue sarcoma diagnoses representing half of all childhood soft tissue sarcomas. In this presentation we will review standard approach in general on diagnosis and management of soft tissue tumors and further discuss how recent molecular work informs diagnosis and management of subgroup of patients.

https://doi.org/10.1016/j.htct.2021.10.958

Sp14

THE APPROACH AND DIAGNOSIS OF COOMBS NEGATIVE HEMOLYTIC ANEMIAS

Achille Iolascon

Anemia affects 1.6 billion of people worldwide, about 10% of these individuals are affected by rare anemias of which 80% are hereditary.[1] Hereditary anemias (HA) embrace a highly heterogeneous group of disorders characterized by anemia of variable degree and by complex genotype-phenotype correlations. Differential diagnosis, classification, and patient stratification among HA are often very difficult.

To date, the major current application of next generation sequencing (NGS) in diagnostics is through disease-targeted tests for which multiple causal genes are known. Some studies have already demonstrated the utility of targeted-NGS (t-NGS) approach in the study of specific subtypes of HA patients. Here, we described the diagnostic workflow based on t-NGS that we developed for the diagnosis of patients affected by HA. Within this wide group of disorders, we included: (1) hyporegenerative anemias, as congenital dyserythropoietic anemias (CDA); (2) hemolytic anemias due to red cell membrane defects, as hereditary spherocytosis (HS) and stomatocytosis (HSt); hemolytic anemias due to enzymatic defects, as pyruvate kinase (PK) deficiency.[1—5]

References

1. Hertz L et al. Is Increased Intracellular Calcium in Red Blood Cells a Common Component in the Molecular Mechanism Causing Anemia? Front Physiol. 2017; 8: 673.
2. Gambale A et al. Diagnosis and management of congenital dyserythropoietic anemias. Expert Rev Hematol. 2016;9 (3):283-96.
3. Andolfo I et al. New insights on hereditary erythrocyte membrane defects. Haematologica. 2016;101(11):1284—1294.
4. Andolfo I et al. Hereditary stomatocytosis: An underdiagnosed condition. Am J Hematol. 2018;93(1):107—121.
5. Canu G et al. Red blood cell PK deficiency: An update of PK-LR gene mutation database. Blood Cells Mol Dis. 2016;57:100—109.

https://doi.org/10.1016/j.htct.2021.10.1102